Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The immunohistochemical analysis using the monoclonal antibodies to the carbohydrate antigens were performed and suggested that CA19-9 is a tumor-associated antigen in gastric cancer, Leb, Ley, CA19-9, CSLEX1, SLX in colorectal cancer and pancreatic cancer, and Lex, Ley, and CSLEX1 in breast and esophageal cancers, respectively. Expression of the type 2 carbohydrate antigens had relation to the prognosis of patients with breast cancer. In colorectal cancer, the patients with high degree of expression of CA19-9 had a poor prognosis, and high risk of distant metastasis. Higher intensity of staining was observed in hepatic in comparison with primary lesion. Thus carbohydrate antigens showed important role as tumor-associated antigens and good indicator for evaluation of prognosis.
 ...
PMID:[Carbohydrate antigens as a tumor-associated antigen and prognostic indicators in carcinomas of the breast, esophagus, stomach, colorectum, and pancreas]. 194 63

A mouse monoclonal antibody ACFH18, produced by immunizing with human gastric cell line MKN-74, recognizes a novel glycolipid antigen, fucosyl-lactoneodecaosylceramide. In the present study, we investigated the immunohistological localization of this antigen and its biochemical detection in glycolipid fraction in normal and malignant human gastric tissue, compared with other tumor-associated type-2 chain glycolipid antigens such as sialyl Lex, sialyl Lex-i and Ley. Reactivity with ACFH18 was detected immunohistologically in the proliferation zone of normal fundic gland region as well as in 38 of 54 cases of gastric cancer, with preferential binding to undifferentiated type cancer. Glycolipids reacting with ACFH18, especially slow-migrating glycolipids on thin-layer chromatography, were accumulated in all of four cancer specimens compared with normal mucosa obtained from the same patients. Many glycolipids with sialyl Lex or sialyl Lex-i epitope were detected in normal mucosa and almost all of these glycolipids were accumulated in cancer specimens. Sialyl LeX-i antigen was increased more specifically in cancer than sialyl LeX was. A Ley antigenic glycolipid was considerably decreased in three of four cancer cases and increased in one case. From these results, glycolipid detected by ACFH18 appeared to be a tumor-associated antigen comparable to sialyl LeX and sialyl Lex-i antigens, but with a unique character as an undifferentiated-type tumor-associated antigen.
 ...
PMID:Immunohistological and biochemical detection of fucosylated polylactosamine antigen with monoclonal antibody ACFH18 in gastric cancer and normal gastric mucosa. 211 68

An affinity column containing L-fucose specific Aleuria aurantia lectin was used for the efficient separation of tumor-associated antigens. Five of six glycoconjugates antigens tested, carcinoembryonic antigen (CEA), CA19-9, sialyl Lewis X-i, DU-PAN-2 and CA125, bound to the affinity gel and eluted in high yield with 20 mM L-fucose, but alpha-fetoprotein, which is known to contain fucose in the carbohydrate chain, passed through the column. This column was also proved to be useful for group separation of CA19-9, sialyl Lewis X-i and Leb antigens from a serum sample with gastric cancer.
 ...
PMID:A simple procedure for isolation of tumor-associated antigens by affinity chromatography using fucose-specific Aleuria aurantia lectin. 221 Aug 5

Two mouse monoclonal antibodies (MoAbs), KM-93 raised against human lung adenocarcinoma and KM-231 raised against human gastric cancer, were useful in serum diagnosis of several human cancer. KM-93 and KM-231 recognize sialyl Lex epitope and sialyl Lea epitope, respectively, expressed on glycoprotein and glycolipid. We established a new "cocktail" sandwich enzyme-linked immunosorbent assay system using the two MoAbs and the advantage of this assay system, which can simultaneously detect sialyl Lex and sialyl Lea antigens, is assessed in the present study. The new assay system is composed of a mixture of KM-93 and KM-231 as 1st antibodies and a mixture of biotinylated two MoAbs as 2nd antibodies. We evaluated the concentration of MoAbs and optimized it to gain high cancer-positivity. This assay system covered sialyl Lex positive and/or sialyl Lea-positive sera and gave a high rate of positive results in lung adenocarcinoma (62.3%), gastric cancer (32.5%), colon cancer (37.5%), pancreatic cancer (83.3%), bile duct and gall bladder cancer (66.7%) and hepatoma (76.9%), whereas positive results in healthy adults remained low. Positive results in benign diseases of lung (12.5%), pancreas (10.8%), gall bladder and bile duct (9.1%) were very low, but were higher in liver cirrhosis (33.3%), hepatitis and liver injury (34.8%). Simultaneous detection of two carbohydrate antigens, sialyl Lex and sialyl Lea was clearly superior to single detection.
 ...
PMID:Advantage of cocktail-use of two anti-tumor monoclonal antibodies, KM-93 and KM-231, in serum diagnosis of cancer. 247 31

(alpha 1----3)-L-Fucosyltransferase activity was measured in serum samples from 90 gastric cancer patients, 10 patients with benign diseases and 100 healthy controls. The enzyme activity was significantly elevated in the serum samples of patients with cancer compared to those from patients with benign diseases (P less than 0.01) and healthy controls (P less than 0.001). The elevation of the enzyme activity was found to correlate strongly with the clinical stage of disease. The sensitivity of (alpha 1----3)-L-fucosyltransferase was also demonstrated to be high in comparison with the tumor-associated antigens, such as carcinoembryonic antigen and sialylated Lewis X-i. Follow-up studies of (alpha 1----3)-L-fucosyltransferase in 11 cancer patients with disease at different stages showed that the enzyme activity could be useful for monitoring the post-surgical course of the disease. These results suggest that (alpha 1----3)-L-fucosyltransferase activity has a clinically important potential as a tumor marker in gastric cancer.
 ...
PMID:Tumor-related elevation of serum (alpha 1----3)-L-fucosyltransferase activity in gastric cancer. 257

The expression of carbohydrate antigens in malignant and non-malignant gastric mucosa was studied immunohistochemically using the monoclonal antibody AH6 directed to Ley antigen, FH2 directed to Lex antigen, and FH6 directed to sialyl-Lex antigen. Formalin-fixed gastric tissue resected from 54 patients with gastric cancer and 20 patients with gastric ulcer were tested. The incidence of positive cases in gastric cancer patients with each antibody was as follows: AH6;85%, FH2;74%, FH6;74%. The Lex antigen was expressed in 81.5% of cases histologically classified as undifferentiated type, and 66.7% of cases classified as differentiated type. It was expressed in a higher incidence in early stage cancer (93.3%) than in advanced stage cancer (66.7%). Sialyl-Lex antigen was detected in more cases of differentiated type (88.9%) than in those of undifferentiated type (59.3%), whereas none of 8 early cancers of undifferentiated type expressed the antigen. The incidence of the expression of Ley antigen did not differ in relation to histological type or invasiveness. Lex and Ley antigens were detected in noncancerous gastric epithelium. Sialyl-Lex antigen was not detected in the normal fundic gland region. These results demonstrate that Lex antigen may be a differentiation-associated antigen, and sialyl-Lex antigen might be useful as a marker of differentiated cancer and an indication for invasion of undifferentiated cancer.
 ...
PMID:Immunohistochemical study of carbohydrate antigen expression in gastric carcinoma. 266 6

Two novel monoclonal antibodies, KL-3 (IgM) and KL-6 (IgG1), which can detect soluble antigens in sera and effusions (molecular weights greater than 1,000 K) were produced against human pulmonary adenocarcinoma VMRC-LCR cells. KL-3 and KL-6 antibodies reacted with asialo- and sialo-carbohydrate antigenic determinants, respectively. Both carbohydrate epitopes appear, from competitive inhibition studies, to be different from Lex, Ley, sialyl Lea and sialyl Lexi which were recognized with FH2, AH6, NS19-9 and FH6 antibodies, respectively. Using an enzyme linked immunosorbent assay, elevated KL-6 antigen levels were frequently observed in the sera of patients with lung adenocarcinoma [52% (17/33)], pancreatic cancer [44% (4/9)] and breast cancer [40% (8/20)], but infrequently in the sera of patients with lung squamous cell carcinoma [18% (4/22)], lung small cell carcinoma [8% (1/13)], gastric cancer [0% (0/19)], colorectal cancer [0% (0/8)] and hepatocellular cancer [13% (1/8)]. The levels and positive rates of serum KL-6 antigen increased with the progression of clinical stage of lung adenocarcinoma. In pleural effusions, the prevalences of lung adenocarcinoma cases with elevated levels of KL-3 and KL-6 antigens were 76% (13/17) and 82% (14/17), respectively. These monoclonal antibodies can define novel soluble antigens in sera and effusions which could be useful in tumor diagnoses and for monitoring tumor progression.
 ...
PMID:Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. 341 86

Sialylated Lewis (S-Lex) has been studied histologically and serologically in stomach cancer by the CSLEX1 monoclonal antibody. S-Lex was expressed in 73.9% of 46 stomach cancer tissues, 29.4% of metaplastic parts adjacent to cancer, and none of six gastric ulcer tissues including metaplasia. Serologically positive percentages were as follows: 26.0% of 100 stomach cancers, 0.9% of 322 benign diseases, and 0.7% of 280 healthy donors in the sera, as well as 72.4% of 29 ascites of stomach cancers and 5.3% of 17 effusions of benign diseases. These findings demonstrate that S-Lex possesses a potential usefulness as a tumor marker in stomach cancer.
 ...
PMID:[Sialylated Lewis x as a tumor-associated antigen in stomach cancer]. 354 Mar 61

Previous studies from our laboratory have shown that benzyl-alpha-GalNAc inhibits the glycosylation of mucin in colon cancer cells. In this study, we determined whether benzyl-alpha-GalNAc inhibits mucin glycosylation in KATO III gastric cancer cells. We also examined its effects on expression of mucin antigens, and compared the mucins made by KATO III with those of a colonic cancer cell line, Caco-2. Results of these experiments suggest that benzyl-alpha-GalNAc (2 mM) inhibited [3H]glucosamine labelling of mucins by 82% in KATO III and by 70% in Caco-2. For both cell lines, the mucin secreted in the presence of benzyl-alpha-GalNAc was less acidic. Both cell lines secreted benzyl-oligosaccharides, but those from KATO III (8-9 sugars) were larger than those from Caco-2 (6-7 sugars). In mucins purified from the medium of treated cells, peripheral carbohydrate antigens (sialyl Lex in KATO III and terminal fucose in Caco-2) were decreased (compared with control), while core carbohydrate antigens (T antigen in both cell lines and sialyl Tn in Caco-2) were increased. Western blots of cell homogenates showed differences between KATO III and Caco-2 in MUC 1 apomucin protein antigens, in sialyl Lex and in sialyl Tn antigens. We conclude that benzyl-alpha-GalNAc does inhibit the glycosylation of mucin in KATO III gastric cancer cells as in human colon cancer cells, but that alterations in mucin antigens occur in a cell line-specific manner.
 ...
PMID:Inhibition of mucin synthesis by benzyl-alpha-GalNAc in KATO III gastric cancer and Caco-2 colon cancer cells. 757 79

Sialyl Lea and sialyl Lex are cancer-associated carbohydrate antigens. The biosynthesis of these antigens is completed by fucosyltransferases. We measured the activity of alpha 1-->4 fucosyltransferase (sialyl Lea synthase) and alpha 1-->3 fucosyltransferase (sialyl Lex synthase) in gastrointestinal cancer tissues. alpha 1-->4 fucosyltransferase activity was similarly detected in most normal or malignant tissues. alpha 1-->3 fucosyltransferase activity in gastric cancer was higher than in the normal mucosa. In colonic cancer, although the enhanced expression of sialyl Lex was observed in 86% of cases, the elevated activity of alpha 1-->3 fucosyltransferase was observed in only 58%. In conclusion, the expression of sialyl Lea and sialyl Lex antigens in the stomach and colon was not controlled solely by fucosyltransferases.
 ...
PMID:[Fucosyltransferase producing sialyl Le(a) and sialyl Le(x) carbohydrate antigen in gastrointestinal cancer]. 763 19


1 2 3 Next >>